The collaboration between Swiss Rockets and daura is designed to facilitate the financing of promising life science projects. With the daura platform, investments in biotech start-ups will be possible digitally even with smaller amounts and without transaction costs.
By selecting research projects in oncology and immunology, the biotech company Swiss Rockets supports a paradigm shift, especially in cancer treatment. Together with universities, the internationally renowned Swiss Rockets teams of experts continuously evaluate new projects. Swiss Rockets invests in those that can achieve a breakthrough in cancer research. These projects form the Swiss Rockets portfolio and are continually being developed.
Daura is the first platform in Switzerland that enables unlisted Swiss corporations to issue their shares independently and digitally and carry out capital increases. The platform also allows efficient digital management of the share register and the holding of digital general meetings. Daura is operated on the blockchain infrastructure of Swisscom and Swiss Post and meets all Swiss security standards.
“With this partnership, Swiss Rockets is breaking new ground and creating a profitable situation in several respects: investors can invest in internationally promising biotech start-ups in a time-efficient manner, and with even small contributions, the start-up companies in turn benefit from the financial support and the business location Switzerland is positively influenced by such initiatives,” Dr. Vladimir Cmiljanovic, Chairman and CEO of Swiss Rockets AG, explains this cooperation.
“Switzerland is known worldwide for its pharmaceutical and financial industries. This is where two innovative players from both sectors join forces to continue to write this history together,” adds Peter Schnürer, CEO of daura AG.
About Swiss Rockets AG:
Swiss Rockets AG, founded in 2018, is implementing a paradigm shift in healthcare. Cancer patients will benefit from new treatments that will be developed using innovative and disruptive methods. The Swiss Rockets team combines the necessary specialist knowledge and experience to efficiently and sustainably break new ground in cancer medicine.
Founder and CEO of Swiss Rockets is Dr. Vladimir Cmiljanovic, a medicinal chemist with more than 15 years of experience developing cancer drugs. Together with his sister Dr. Natasa Cmiljanovic, co-founder and Chief Scientific Officer of Swiss Rockets, he developed oncology drugs at the University of Basel and subsequently founded and successfully led several biotech companies. Manuel Ebner, Strategic Advisor of Swiss Rockets and CEO Switzerland at Bank of America Merrill Lynch, and Dr. Thomas Sander, Scientific Advisor and one of the first employees of the biotech company Actelion, are co-founders of Swiss Rockets AG.
The Board of Directors of Swiss Rockets AG is chaired by Dr. Vladimir Cmiljanovic, a successful entrepreneur and the founder of Swiss biotech companies PIQUR and TargImmune. Other board members are Prof. Dr. Michael N. Hall, a renowned researcher, and Professor at the Biozentrum of the University of Basel; Dr. Natasa Cmiljanovic, a medicinal chemist and clinical scientist with wide experience in oncology drug development; Dr. Thomas Ladner, a business lawyer, founder or co-founder of several successful start-ups and the WORLD.MINDS Foundation; André Debrunner, a financial expert and fund manager at Northern Trust Corporation Switzerland.
About daura AG:
The technology company daura uses the Blockchain to digitize shares of small, medium and established companies from Switzerland. Using the daura platform, the processing of capital increases becomes cheaper, the administration of the share register easier, general meetings more efficient, and a wide range of people can be bound to the company with shares. Shareholders on the platform gain access to new investment opportunities in Swiss SMEs and can manage their company shares digitally themselves via daura. Daura is a joint venture of the established and innovative Swiss partners Swisscom, SIX, Sygnum, Luka Müller (MME), and Christian Wenger (Wenger & Vieli).